Gainers & Losers Of Aug.17: GTHX, CDTX, KMDA, ACHC, EDIT...

(RTTNews) - The following are some of the biotech stocks that made their way onto the Day's Gainers & Losers' list of August 17, 2017.

GAINERS

1. G1 Therapeutics Inc. (GTHX)

Gained 12.04% to close Thursday's (Aug.17) trading at $15.63.

News: No news

The Company made its debut on the NASDAQ on May 17, 2017, offering its shares at a price of $15.00 each.

Pipeline:

The Company has 3 drug candidates in its pipeline namely, Trilaciclib, G1T38 and G1T48.

Trilaciclib is under four Phase 2 clinical trials - three studies in patients with small-cell lung cancer (SCLC), and one study in patients with triple-negative breast cancer. G1T38 is under a phase 1b/2a study for the treatment of ER+, HER2- breast cancer. G1T48 is currently in IND-enabling studies, and is on track for Phase 1 clinical development in the fourth quarter of 2017.

Near-term catalysts:

-- Investigational New Drug application filing for G1T38 in non-small cell lung cancer is expected in the fourth quarter of 2017. -- IND filing for G1T48 in ER+, HER2- breast cancer is expected in the fourth quarter of 2017. -- Top-line data from a phase 2a study of Trilaciclib in first-line small-cell lung cancer are expected in the first quarter of 2018. -- Enrollment for the phase 2a trial of Trilaciclib in second/third-line small-cell lung cancer is expected in the second quarter of 2018. -- Preliminary Phase 1b data for G1T38 plus Faslodex in ER+ breast cancer are anticipated in the second quarter of 2018.

2. Cidara Therapeutics Inc. (CDTX)

Gained 11.64% to close Thursday's trading at $6.47.

News: No news

Near-term catalyst:

A phase II trial of CD101 IV in candidemia, dubbed STRIVE, is ongoing. This study is comparing the safety and efficacy of CD101 IV to standard-of-care therapy, Caspofungin with an optional step-down to oral fluconazole. The top line data from the STRIVE study are anticipated in the fourth quarter (Q4, 2017).

3. Horizon Pharma Public Ltd. Co. (HZNP)

Gained 10.51% to close Thursday's trading at $13.14.

News: No news

Recent event:

On August 7, 2017, the Company reported strong second-quarter sales results and raised its full-year sales outlook.

Second-quarter net sales were $289.5 million, an increase of 12 percent compared to the second quarter of 2016, driven by continued strong growth from the Company's orphan and rheumatology business units.

On a non-GAAP basis, the net income for the recent second quarter dropped to $68.3 million or $0.41 per share from $91.3 million or $0.56 per share in the year-ago quarter.

Looking ahead, the Company increased its full-year 2017 net sales guidance range to $1.010 billion to $1.045 billion from its prior forecast of $985 million to $1.020 billion.

4. Aerie Pharmaceuticals Inc. (AERI)

Gained 4.98% to close Thursday's trading at $54.80.

News: No news

Near-term catalysts:

-- The Company's phase III trial of Roclatan, its experimental glaucoma product to lower IOP, to be conducted in Europe for European markets, dubbed Mercury 3, is set to commence in the third quarter of 2017. -- The Company's New Drug Application for Rhopressa for the treatment of glaucoma or ocular hypertension is under FDA review, with an action due on February 28, 2018. -- The submission of Roclatan NDA is anticipated in the first half of 2018.

5. Kamada Ltd. (KMDA)

Gained 4.09% to close Thursday's trading at $4.45.

News: No news

Near-term catalyst:

-- The Company's anti-rabies immune globulin (IgG) therapy is under FDA review, with a decision expected to be announced by August 29, 2017. This anti-rabies therapy has been sold in numerous territories outside of the U.S. since 2003 under the brand name KamRAB by Kamada.

LOSERS

1. ProQR Therapeutics NV (PRQR)

Lost 12.12% to close Thursday's trading at $4.35.

Recent event:

On August 16, 2017, the Company reported results for the second quarter of 2017.

Net result for the recent second quarter was a €11.3 million loss or €0.47 per share, compared to a €10.0 million loss or €0.43 per share for the same period last year. At June 30, 2017, the Company had cash and cash equivalents of €42.3 million.

Near-term catalyst:

-- Top-line data from phase 1b clinical trial of QR-010 in cystic fibrosis is expected to be announced in September.

2. Leap Therapeutics Inc. (LPTX)

Lost 9.77% to close Thursday's trading at $5.91.

News: No news

Pipeline:

The Company's lead clinical candidate is DKN-01, which is under phase I/II trials in esophageal cancer and cholangiocarcinoma, a form of bile duct cancer. Another clinical candidate of the company is TRX518, currently in phase I clinical trials in solid tumor malignancies.

3. Regenxbio Inc. (RGNX)

Lost 9.71% to close Thursday's trading at $20.00.

News: No news

Near-term catalysts:

-- A phase I clinical trial evaluating RGX-314 for the treatment of wet age-related macular degeneration (wet AMD) is underway and an interim update from the trial is expected to be provided by the end of 2017. -- A phase I/II clinical trial evaluating RGX-501 for the treatment of homozygous familial hypercholesterolemia (HoFH) is ongoing - with an interim update expected by the end of 2017.

4. Editas Medicine Inc. (EDIT)

Lost 9.35% to close Thursday's trading at $18.80.

News: No news

Upcoming Events:

Editas Medicine will participate in the following upcoming investor conferences:

-- Morgan Stanley Global Healthcare Unplugged Conference, September 11-13, New York City -- Chardan Gene Therapy Conference, October 10, New York City and -- Jefferies Gene Therapy/Editing Summit, October 12, New York City.

Editas Medicine will also participate in the following upcoming scientific and medical conference:

-- European Society of Gene & Cell Therapy, October 17-20, Berlin.

5. Acadia Healthcare Co. Inc. (ACHC)

Lost 9.08% to close Thursday's trading at $46.99.

News: The Company has announced a secondary offering of 2.82 million shares of its common stock, par value $0.01 by investment funds affiliated with Waud Capital Partners, L.L.C., investment funds affiliated with Bain Capital Investors, LLC, and certain current officers and directors of the Company.

The Company will not receive any proceeds from the offering.

6. Roka Bioscience Inc. (ROKA)

Lost 8.75% to close Thursday's trading at $2.00.

News: The Company has agreed to sell its assets to Rokabio Inc., a newly formed, wholly-owned subsidiary of Institute for Environmental Health Inc. for $17.5 million in cash.

The deal is subject to certain adjustments set forth in the asset purchase agreement. As part of the transaction, Roka Bioscience will be required to make a $2.5 million milestone payment pursuant to its license agreement. The asset sale is the initial step in a contemplated liquidation of Roka Bioscience. Stockholder approval will also be required for the plan of liquidation.